Drugs / Taladegib
Taladegib
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT07454291 | Apr → Oct 2026 expected | idiopathic pulmonary fibrosis | Endeavor Biomedicines, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05817240 | May → Jun 2023 | idiopathic pulmonary fibrosis | Endeavor Biomedicines, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02784795 | Nov 2016 → Aug 2018 | breast cancer, cholangiocarcinoma, colon carcinoma, soft tissue sarcoma | Eli Lilly and Company | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01919398 | Aug 2013 → May 2016 | metastatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01697514 | Jul 2013 → Jul 2016 | childhood medulloblastoma, rhabdomyosarcoma | Eli Lilly and Company | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01746745 | Jan → Mar 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01681186 | Sep → Dec 2012 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01226485 | Sep 2010 → Jan 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02530437 | Mar 2017 → Jan 2022 | esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT01722292 | Jan 2013 → Feb 2015 | small cell lung carcinoma | Eli Lilly and Company | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04968574 | Aug 2021 → Nov 2023 | idiopathic pulmonary fibrosis | Endeavor Biomedicines, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-04-04 | Eli Lilly and Company | Results Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer lilly.com ↗
Lilly scientists have identified an orally administered anti-cancer agent, LY2940680, which, in preclinical studies, disrupted the abnormal signaling of a key regulator of embryonic cell development. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-04-04 | Eli Lilly and Company | Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer lilly.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | taladegib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07454291 ↗ |
| Known as | [^14C]-LY2940680 | “Single 100 milligram (mg) dose of LY2940680 containing 100 microCuries of carbon-14-labeled LY2940680 ([^14C]-LY2940680)” NCT01746745 ↗ |
| Known as | ENV-101 | “The goal of this clinical trial is to learn about the potential effect of ENV-101 (taladegib) on the pharmacokinetics of nintedanib (an approved treatment for idiopathic...” NCT05817240 ↗2“We aimed to assess the safety and efficacy of taladegib (ENV-101), an Hh pathway inhibitor, in IPF in a phase 2a, proof-of-concept clinical trial.” PMID 41043447 ↗ Sep 2025 “taladegib (ENV-101)” NCT07454291 ↗ |
| Known as | LY2940680 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01919398 ↗ |
| Action | Inhibit | “Hedgehog/SMO Antagonist” NCT01722292 ↗ |
| Route | Oral | “administered orally” NCT01226485 ↗ |
| Target | SMO | “Hedgehog/SMO Antagonist” NCT01722292 ↗ |